ARDX - Ardelyx, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.85
-0.05 (-1.02%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.90
Open4.85
Bid4.50 x 200
Ask5.35 x 800
Day's Range4.80 - 5.10
52 Week Range4.05 - 14.10
Volume412,667
Avg. Volume320,038
Market Cap230.877M
Beta1.39
PE Ratio (TTM)N/A
EPS (TTM)-1.36
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.71
Trade prices are not sourced from all markets
  • GlobeNewswire16 days ago

    Analysis: Positioning to Benefit within Euronet Worldwide, Innospec, Zosano Pharma, Ardelyx, Crown Castle International, and Aldeyra Therapeutics — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, April 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • PR Newswirelast month

    Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in Canada

    FREMONT, Calif., March 19, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced a license agreement with Knight Therapeutics, Inc. (GUD.TO) (Knight) that provides Knight with exclusive rights to commercialize tenapanor in Canada. Tenapanor is Ardelyx's oral, first-in-class small molecule treatment that has completed Phase 3 development for irritable bowel syndrome with constipation (IBS-C) and is being evaluated in a second Phase 3 study for hyperphosphatemia.

  • Associated Presslast month

    Ardelyx posts 4Q profit

    The Fremont, California-based company said it had net income of 21 cents per share. The biotechnology company posted revenue of $42 million in the period. For the year, the company reported that its loss ...

  • PR Newswirelast month

    Ardelyx Reports 2017 Financial Results and Appoints Industry Veteran, Jan Lundberg, Ph.D., to Board of Directors

    Enrollment Underway in Second Registration Study of Tenapanor for Hyperphosphatemia NDA for Tenapanor for IBS-C on Track for Submission in Second Half of 2018 FREMONT, Calif. , March 14, 2018 /PRNewswire/ ...

  • GlobeNewswire2 months ago

    Consolidated Research: 2018 Summary Expectations for Progress Software, Cracker Barrel Old Country Store, Natural Grocers by Vitamin Cottage, VBI Vaccines, Ardelyx, and CytomX Therapeutics — Fundamental Analysis, Key Performance Indications

    NEW YORK, Feb. 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Progress ...

  • PR Newswire2 months ago

    Ardelyx Announces Departure of Chief Scientific Officer

    FREMONT, Calif., Feb. 12, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced that Jeremy Caldwell, Ph.D., chief scientific officer, will be leaving the company, effective February 16, 2018, to pursue a position as chief executive officer of an early stage biotech start-up company based in San  Diego. "Jeremy has been a tremendous asset to Ardelyx, and I am incredibily grateful for his many contributions to the company and our programs over the years," said Mike Raab, president and chief executive officer of Ardelyx. "My time with Ardelyx has been extremely rewarding, and I'm proud of the many accomplishments of this team," said Jeremy.

  • PR Newswire2 months ago

    Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference

    FREMONT, Calif., Feb. 8, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference at 2:00 p.m. ET on Thursday, Feb. 15, 2018 in New York City. To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. Ardelyx is focused on enhancing the way people with cardiorenal diseases are treated by developing differentiated, minimally systemic medicines.

  • Best NasdaqGM Growth Stocks
    Simply Wall St.3 months ago

    Best NasdaqGM Growth Stocks

    Companies that have significant growth prospects for profitability and returns can add tangible upside to your portfolio. Ardelyx and eMagin are examples of many potential outperformers that analysts are bullishRead More...

  • 5 Great Breakout Stocks Offering Superlative Returns
    InvestorPlace3 months ago

    5 Great Breakout Stocks Offering Superlative Returns

    In order to select the right breakout stock one has to first calculate its support and resistance level. A support level is the lower bound for stock movements while a resistance level refers to the maximum price which it trades within over a considerable period. In other words, the demand for a stock is at its lowest at its support level, which means most traders are willing to sell it.

  • Zacks.com highlights: Sanchez Midstream Partners, Tecnoglass, Aeterna Zentaris, Ardelyx and Matrix Service
    Zacks3 months ago

    Zacks.com highlights: Sanchez Midstream Partners, Tecnoglass, Aeterna Zentaris, Ardelyx and Matrix Service

    Zacks.com highlights: Sanchez Midstream Partners, Tecnoglass, Aeterna Zentaris, Ardelyx and Matrix Service

  • 5 Great Breakout Stocks Offering Superlative Returns
    Zacks3 months ago

    5 Great Breakout Stocks Offering Superlative Returns

    This method involved zeroing in on those stocks whose prices are varying within a narrow band.

  • Can The Uptrend Continue for Ardelyx (ARDX)?
    Zacks4 months ago

    Can The Uptrend Continue for Ardelyx (ARDX)?

    Investors certainly have to be happy with Ardelyx Inc (ARDX) and its short term performance

  • Ardelyx Inc (NASDAQ:ARDX): Is It A Good Long Term Opportunity?
    Simply Wall St.4 months ago

    Ardelyx Inc (NASDAQ:ARDX): Is It A Good Long Term Opportunity?

    The most recent earnings release Ardelyx Inc’s (NASDAQ:ARDX) announced in September 2017 suggested that losses became smaller relative to the prrior year’s level as a result of recent tailwinds InvestorsRead More...

  • PR Newswire4 months ago

    Ardelyx Announces Presentation at J.P. Morgan 36th Annual Healthcare Conference

    FREMONT, Calif., Jan. 3, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present a company overview at the J.P. Morgan 36th Annual Healthcare Conference on Wednesday, Jan. 10, 2018 at 10 a.m. PT. To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor page of the Ardelyx website at ir.ardelyx.com. Ardelyx is focused on enhancing the way people with cardiorenal diseases are treated by developing differentiated, minimally systemic medicines.

  • PR Newswire4 months ago

    Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C

    FREMONT, Calif., Jan. 3, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced that the company successfully completed the safety extension portion of its Phase 3 T3MPO program, designed to support the registration of tenapanor for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). Of patients treated, 9.2 percent reported experiencing diarrhea, with only 1.7 percent of patients discontinuing treatment due to diarrhea. "We are very excited to see that tenapanor was so well-tolerated in patients treated for up to a year, resulting in minimal treatment discontinuations," said David P. Rosenbaum, Ph.D., chief development officer of Ardelyx.

  • January Growth Stock Opportunities
    Simply Wall St.4 months ago

    January Growth Stock Opportunities

    Five Prime Therapeutics and Ardelyx can add profound upside to your portfolio. This is because the optimistic growth outlook for their profitability and returns make their high-growth potential appealing relativeRead More...

  • Why Ardelyx (ARDX) Could Beat Earnings Estimates Again
    Zacks4 months ago

    Why Ardelyx (ARDX) Could Beat Earnings Estimates Again

    Ardelyx (ARDX) boasts a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.

  • PR Newswire4 months ago

    Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China

    FREMONT, Calif., Dec. 11, 2017 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced that the company has entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited (Fosun Pharma) providing Fosun Pharma with the exclusive rights to develop and commercialize Ardelyx's lead product, tenapanor, in China for the treatment of patients with irritable bowel syndrome with constipation (IBS-C) and for the treatment of hyperphosphatemia related to chronic kidney disease. Tenapanor is an investigational oral, minimally systemic NHE3 inhibitor discovered and developed by Ardelyx. Under the terms of the agreement, Ardelyx will receive an upfront payment of $12 million and is eligible to receive additional milestones of up to $113 million, as well as tiered royalty payments on net sales ranging from the mid-teens to 20 percent.

  • Zacks.com featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTime
    Zacks5 months ago

    Zacks.com featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTime

    Zacks.com featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTime

  • 5 Affordable Breakout Stocks Offering Excellent Returns
    Zacks5 months ago

    5 Affordable Breakout Stocks Offering Excellent Returns

    If properly implemented, such a strategy has the ability to deliver impressive returns.

  • TheStreet.com5 months ago

    Ardelyx Jumps on License Deal; Otonomy Rises on Otividex News -- Biotech Movers

    The Fremont, Calif.-based firm and Kyowa Hakko Kirin signed a license pact for Ardelyx's lead investigational product, tenapanor.

  • PR Newswire5 months ago

    Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan

    FREMONT, Calif. and TOKYO, Nov. 28, 2017 /PRNewswire/ -- Ardelyx, Inc. (ARDX) and Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, "Kyowa Hakko Kirin"), today announced that they have entered into a license agreement that provides Kyowa Hakko Kirin with exclusive rights to develop and commercialize Ardelyx's lead investigational product, tenapanor, for the treatment of cardiorenal diseases, including hyperphosphatemia, in Japan. Tenapanor is an oral, minimally systemic NHE3 inhibitor discovered and developed by Ardelyx that is in Phase 3 development in the United States for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) who are on dialysis.

  • TheStreet.com5 months ago

    Cytokinetics Shares Plunge on Study Results for ALS Drug -- Biotech Movers

    The South San Francisco, Calif.-based firm said its Phase 3 study of tirasemtiv in patients with amyotrophic lateral sclerosis did not achieve primary or secondary endpoints.

  • PR Newswire5 months ago

    Ardelyx Announces Updated Development Path for its Cardiorenal Pipeline

    FREMONT, Calif., Nov. 21, 2017 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today provided an update on the development of its cardiorenal pipeline. The company's second registration study for tenapanor for the treatment of hyperphosphatemia will begin enrolling shortly, after having received feedback from the United States Food and Drug Administration (FDA) on the trial design. The company believes this will limit the commercial potential of RDX7675 and, as a result, has decided to discontinue development of RDX7675.

  • Associated Press5 months ago

    Ardelyx reports 3Q loss

    On a per-share basis, the Fremont, California-based company said it had a loss of 44 cents. Ardelyx shares have declined 61 percent since the beginning of the year. The stock has fallen 57 percent in the ...